ÂÒÂ×ÊÓƵ COVID-19 CLINICAL GUIDANCE
The Taskforce
ÂÒÂ×ÊÓƵ Clinical Guidance Task Force
COVID-19 was declared a world pandemic on March 11. Patients with addiction are a vulnerable population with unique challenges in light of COVID-19. Many patients with addiction have other co-occurring conditions and depending on the severity of their disease and access to economic and social support, such individuals may cycle in and out of emergency departments, addiction treatment centers, homeless shelters and other facilities. These circumstances pose unique challenges regarding COVID-19 transmission and the severity of the illness if contracted by patients with SUD. At the very least proper attention to infectious disease issues will decrease the infection rate among this population and their families.
This Task Force is charged to develop guidance resources for clinicians to use as they sort out how to handle the impact of COVID-19 on their practice and in the treatment of patients with addiction.
As of: 4/17/20
Task Force Members
Yngvild Olsen, MD, MPH, DFÂÒÂ×ÊÓƵ Chair
Kelly Clark, MD, MBA, DFAPA, DFÂÒÂ×ÊÓƵ Vice Chair
Anika Alvanzo, MD, MS, FACP, DFÂÒÂ×ÊÓƵ
Gregory X. Boehm, MD, DFÂÒÂ×ÊÓƵ
Chris Bundy, MD, MPH, FÂÒÂ×ÊÓƵ
Megan Buresh, MD
Chinazo O. Cunningham, MD, MS, FÂÒÂ×ÊÓƵ
Itai Danovitch, MD, MBA, FAPA, DFÂÒÂ×ÊÓƵ
Laura Fanucchi, MD, MPH, FÂÒÂ×ÊÓƵ
Kevin Fiscella, MD, MPH. FÂÒÂ×ÊÓƵ
David Goodman, MD
P. Bradley Hall, MD, DABAM, DFÂÒÂ×ÊÓƵ
Scott L. Hambleton, MD, DFÂÒÂ×ÊÓƵ
Brian Hurley, MD, MBA, DFÂÒÂ×ÊÓƵ
Margaret A. Jarvis, MD, DFÂÒÂ×ÊÓƵ
Hendree Jones, PhD
Sarah Kawasaki, MD, FÂÒÂ×ÊÓƵ
Bobby P. Kearney, MD, FÂÒÂ×ÊÓƵ
George Kolodner, MD, DLFAPA, FÂÒÂ×ÊÓƵ
Miriam Komaromy, MD, FACP, DFÂÒÂ×ÊÓƵ
Ilse Levin, DO, MPH&TM, FACP
Marjorie Meyer, MD
Julio Meza, MD
Lewis Nelson, MD, FÂÒÂ×ÊÓƵ
Cara A. Poland, MD, MEd, DFÂÒÂ×ÊÓƵ
Alexis Polles, MD
Shawn Ryan, MD, MBA, FÂÒÂ×ÊÓƵ
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFÂÒÂ×ÊÓƵ
Jasleen Salwan, MD, MPH
Jessie Schaumburg, MD
Lea Selitsky, MD
Jeffrey Selzer, MD, DFÂÒÂ×ÊÓƵ
Nishant Shah, MD
Robert C. Sherrick, MD, FÂÒÂ×ÊÓƵ
Mishka Terplan, MD, MPH, FACOG, DFÂÒÂ×ÊÓƵ
Kinna Thakarar, MD, DO, MPH, FÂÒÂ×ÊÓƵ
Paul Trowbridge, MD
Corey Waller, MD, MS, DFÂÒÂ×ÊÓƵ, FACEP
Sarah Wakeman, MD, FÂÒÂ×ÊÓƵ
Tricia Wright, MD, MS, FACOG, DFÂÒÂ×ÊÓƵ
Content Reviewers
Kelly Clark, MD, MBA, DFAPA, DFÂÒÂ×ÊÓƵ Vice Chair
Paul Earley, MD, DFÂÒÂ×ÊÓƵ ÂÒÂ×ÊÓƵ President
Ken Freedman, MD, MS, MBA, FACP, AGAF, DFÂÒÂ×ÊÓƵ
Margaret Jarvis, MD, DFÂÒÂ×ÊÓƵ
Yngvild Olsen, MD, MPH, DFÂÒÂ×ÊÓƵ Chair
ÂÒÂ×ÊÓƵ Staff
Maureen Boyle, PhD
Kelly Corredor, JD
Anna Garbar
Nailah Harrell
Leigh Hause-Alvarado, MBA, LMHC
Zach Semple
Request a Taskforce Expert
If you are looking for subject matter experts for your virtual sessions or webinars? ÂÒÂ×ÊÓƵ can help you and your organization get in contact with members of our COVID-19 task force.
In order to begin the process of connecting your team with an expert, please send an inquiry to COVID@asam.org and respond to the following questions:
Which topic area are you seeking expert assistance?- Care in Opioid Treatment Programs
- Office-Based Buprenorphine Treatment
- Addiction Treatment in Criminal justice Settings or During Re-entry
- Drug Testing Protocols
- Addiction Treatment in Hospitals
- Infection Mitigation in Outpatient Settings
- Infection Mitigation in Residential Treatment Facilities
- Treating Addiction in Homeless Populations
- Considerations for Medication Selection, Dosage or Formulation
- National & State Regulatory Changes
- Pregnancy & OUD
- Telehealth for Addiction Treatment
- Support Group Participation
Additional questions that will help us find the right expert
- Are you in need of a specific area of expertise?
- Which city/state are you located in?
- Does the expert need to have knowledge of your state?
- What are your proposed dates?
- Are you providing an honorarium?